Page 2 - Strides Pharma

Strides Pharma shares zoom 8% on US FDA approval for Ursodiol tablets

Ursodiol is used for treatment of patients with primary biliary cirrhosis (PBC)

We are looking at vaccines as new growth pivot: Strides Pharma chief

In a Q&A, pharma major's MD & CEO, R Ananthanarayanan says the firm is setting up a vaccine suite and is in final-stage talks with global players to seal a deal for developing a Covid-19 vaccine

Strides Pharma gets DGCI approval to test potential Covid-19 drug

Glenmark was the first Indian firm to get approval from regulator to conduct trials on Favipiravir tablets, which are otherwise used to treat influenza

Strides Pharma to conduct trials for potential Covid-19 drug Favipiravir

Favipiravir is manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug in the country in 2014

Drug to treat Covid-19 ready, says Strides Pharma; stock rises 20%

Firm says will apply to Indian pharma authorities to start studies

Strides Pharma posts threefold rise in profit-before-tax at Rs 103.6 crore

The Bengaluru-headquartered company posted a 358 per cent rise in net profit at 101 crore as compared to the corresponding quarter of the previous financial year

Strides Pharma likely to launch affordable insulin from Stelis stable

The Bengaluru-headquartered company believes Stelis could be a disruptor in insulin accessibility and affordability.

Ranitidine cancer threat: Expect more clarity on products in coming weeks

Ranitidine sales account for 2 per cent of Strides sales and 6 per cent of its profit after tax

Strides Pharma posts Rs 140 crore profit before tax for September quarter

It had posted a loss of Rs 8.70 crore for the corresponding period of FY19.

Strides Pharma resumes sales of antacid drug Ranitidine in Australia

Strides predominantly sells Ranitidine tablets in the US markets

Strides acquires USFDA approved manufacturing facility in Florida

Strides Pharma Science said the site has undergone several successful USFDA inspections and has no outstanding observations

Strides Pharma soars 12% after Co announces JV with Chinese firm

Strides Pharma Global Pte (Singapore) and Sun Moral International (Hong Kong), a wholly-owned subsidiary of Sihuan Pharmaceutical Holdings, have entered into a JV to form called Sihuan Strides.

Strides Pharma announces JV with Chinese firm to launch its products

The development comes in the backdrop of the recent regulatory developments in China which has enabled fast track approvals of differentiated high-quality generics approved in key regulated markets

Strides Bengaluru unit gets 'Voluntary Indicated Action' status from USFDA

The flagship facility in Bengaluru is the largest manufacturing facility for the company with capabilities to produce finished dosage products across multiple formats

US health regulator wants action against Strides Pharma's Puducherry unit

USFDA has classified the facility as OAI based on the inspection conducted from January 28 to February 5, 2019

Strides Pharma gains 6% as JV receives approval for Albendazole tablets

The stock moved higher by 6.4% to Rs 458 on BSE after the company announced that its JV has received USFDA nod for tapeworm infection treatment drug.

Strides Pharma Q2 net loss at Rs 87 million on poor operating income

Consolidated revenue also saw a marginal degrowth of 4.6 per cent at Rs 7.3 billion

Strides Pharma to get $20 mn funding for consumer healthcare business

The stocks of Strides Pharma Science were trading flat at Rs 426.35 per scrip on the BSE, up 3.05 per cent over its previous close

Strides Pharma receives USFDA approval for antiepileptic drug Gabapentin

The product will be marketed by Strides Pharma Inc in the US market

Strides Pharma gets US FDA approval for hypokalemia treatment drug

The tablets, used to treat hypokalemia, will be available in 600 mg and 750 mg dosage